Actinogen Medical announced the appointment of Mr. William (Will) Souter as full time Chief Financial Officer, commencing on 5 February 2024. The Company thanks outgoing part time CFO Mr. Jeff Carter for his valuable service and contribution to the Company. Mr. Carter has adeptly led the finance function over the past three years as the Company has grown its clinical operations to encompass four separate clinical trials.

He has provided key strategic financial insights to the CEO and Board and successfully managed complex R&D tax incentive submissions during this period. Mr. Carter has resigned with effect from 30 November 2023. Mr. Souter brings the right blend of skills and capital markets experience required for the next phase of the Company's development.

In his most recent role as CFO of Atomo Diagnostics Limited, Mr. Souter played a key role in successfully closing a capital raising and initial public offering (IPO) of shares, was a trusted board advisor, managed the finance function, provided critical guidance, leadership and input to corporate operations and management, and conducted investor roadshows and presentations. Mr. Souter is also an experienced non-executive director, having helped Montem Resources Limited through an ASX IPO in 2020 and has successfully led debt financing for a global private industrial business to facilitate a local acquisition. Previously, Mr. Souter was the CFO and Board Advisor at Verton Technologies Australia, an Executive Director at RFC Ambrian, and Director at PricewaterhouseCoopers.

Mr. Souter has a Bachelor of Laws and Commerce from the University of Adelaide, is a Graduate Member of the Australian Institute of Company Directors and has a Graduate Diploma of Legal Practice (admitted to the Supreme Court of NSW).